Maci 3CM x 5CM implant sheets
Ended Awarded
- Contract number
- SPE2DB25FUJQE
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $61,903
Award facts
- Contract value 100% obligated
- $61,902.91 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $61,902.91 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. The award, issued on June 18, 2025, with an ultimate completion date of July 11, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
MACI implants are specialized surgical products used in cartilage repair and regenerative medicine applications, supporting the military healthcare system's surgical and orthopedic capabilities. DMS Pharmaceutical Group's role as a regional prime vendor under the broader $30.3 billion PPV-G GEN V acquisition strategy positions the company as a critical pharmaceutical and medical consumables supplier for Department of Defense healthcare operations globally. The company's extensive product portfolio encompasses oncology treatments, biologics, vaccines, emergency medications, and specialty surgical products, with this delivery order representing one of numerous awards demonstrating consistent contract performance across multiple therapeutic categories serving military medical facilities.
Quick answers
Who was awarded contract SPE2DB25FUJQE?
SPE2DB25FUJQE was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on June 18, 2025.
How much is contract SPE2DB25FUJQE worth?
The government has obligated $61,903 on SPE2DB25FUJQE.
Is contract SPE2DB25FUJQE an order under another contract?
Yes. SPE2DB25FUJQE is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB25FUJQE competed?
The extent of competition for SPE2DB25FUJQE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award